Global Expansion Sepax is planning to move operations from Delaware to Glasgow, UK, and establish a $100 million headquarters in Glasgow Commons Park, signaling a proactive international growth strategy. This presents a sales opportunity to position advanced chromatography products and services for both the new European footprint and potential relocation customers in the region.

Strategic Partnerships Past collaboration with Xperential Scientific indicates openness to partner-based growth in chromatography consumables, bulk media, and LC components. There is an opportunity to propose co-developed or bundled solutions, supported by integration with Sepax’s high-performance HPLC columns and media.

Biologics Focus Sepax serves a broad biologics portfolio including mAbs, bispecifics, ADCs, recombinant proteins, AAVs, VLPs, and nucleic acids. This breadth suggests upsell potential for targeted purification media, process development services, and analytical characterization tools tailored to each modality.

Capacity & Growth With 51-200 employees and revenue in the multi-million range, Sepax is in a growth phase with ongoing headcount expansion noted in 2023. This signals demand for scalable manufacturing solutions, upgraded chromatography media, and performance columns suitable for increasing production scale.

Industry Position Sepax emphasizes reproducibility, high-resolution performance, and real-workflow durability in bioprocessing. A compelling angle for sales conversations is to frame Sepax as a provider of reliable, compliant purification solutions that reduce rework and improve throughput for biologics developers and manufacturers facing regulatory and supply-chain pressures.